RT-PCR analysis of p73 splice variants, ease or tease? Leukemia (2005) The gene TP73 has been identified as a homologue of tumour suppressor TP53 and is expressed from 1p36, a region frequently deleted in human cancers.
1 TP73 is expressed from two distinct promoters, which results in TAp73 and DNp73 isoforms. TAp73 isoforms contain a transactivation domain and are able to act as transcription factors and transactivate p53 target genes like p21 WAF1/Cip1 and 14-3-3s. DNp73 isoforms lack the transactivation domain and can inhibit the function of TAp73 isoforms and p53. TP73 also presents a wide array of C-terminal splice variants called a, b, g, d, e, Z and z. The resulting p73 proteins have different biological functions and are involved in development, apoptosis, cell-cycle arrest and oncogenesis. Several types of leukemia and solid tumours express much higher levels and alternative combinations of p73 splice variants compared to the tissue from which they originated.
1,2 Hence, the identification of all possible splice variants is essential to fully understand the involvement of TP73 in carcinogenic transformation. However, contrasting results regarding p73 mRNA expression in haematopoietic malignancies obtained by different investigators have been noted. 2 RT-PCR is a simple and easy method that has been frequently used to identify C-terminal p73 splice variants expressed in various human cell types and tissues. By choosing PCR primers outside the region spliced out, several p73 forms can be identified simultaneously. [3] [4] [5] [6] Based on results obtained Figure 1 (a) RT-PCR analysis of C-terminal p73 splice variants in SCC15 cDNA. PCR was performed with primers in exons 8 and 14 of p73, 4 using 1 ng of plasmids pcDNA3TAp73a, pcDNA3TAp73g, pcDNA3TAp73d and increasing amounts (2, 4, 6 or 8 ml) of SCC15 cDNA as template. SCC15 cells were cultured at 371C under 5% CO 2 in DMEM/F12 (ratio 3:1) supplemented with 5% foetal bovine serum (HyClone) and 0.4 mg/ml hydrocortisone (Sigma). RNA was isolated with TRIzol s (invitrogen) and in RT reactions Super-RT (Sphaero Q) was used as described by the manufacturers. PCR was carried out for 35 cycles (20 s, 941C; 30 s, 531C; 1 min, 721C) after a 10 min 'hot start' at 941C and followed by final elongation at 721C for 5 min. The reaction mixture contained 20 pmol of each primer, 1.25 units of AmpliTaqGOLDt (Roche) and 1.5 mM MgCl 2 in a total volume of 50 ml. Control PCR products were run on a 1% agarose gel together with SCC15 cDNA PCR products. DNA was transferred to Hybond-N (Amersham) and hybridised with a p73 specific probe. HaCaT (immortal keratinocyte cell line) and HeLa cells (cervix carcinoma) were cultured in DMEM supplemented with 10% foetal bovine serum. HCT116 cells (colorectal carcinoma) were cultured in RPMI1640 supplemented with 10% foetal bovine serum (Hyclone). Primary human keratinocytes were isolated from foreskin derived from circumcision and grown in serum-free medium (KSFM; Gibco). Primary human fibroblasts were grown in DMEM/F10 in a 1:1 ratio, supplemented with 10% foetal bovine serum (Hyclone). All cells were grown at 371C under 5% CO 2 . The controls for p73a, p73g and p73d are the same as in Figure 1a . The control band for p73Z is the 221 bp PCR product of SCC15 cells. The p73 specific probe was made by digestion with Afl3 (exon 9) of a PCR product with 5 0 -GTCACCGGCAGGCAGAGC (exon 6) and 5 0 -GCTCT CTTTCAGCTTCATCAGG (exon 10) on pcDNA3p73a (the largest fragment was used as probe).
by this method specific p73 splice variants have been linked to various forms of leukemia. 3, 6 In an effort to further validate this approach, we have tested whether the detection of all C-terminal p73 splice variants expressed in a given tissue is independent of the total amount of cDNA analysed. For this purpose, we have used four different concentrations of cDNA derived from cultured SCC15 cells (human squamous cell carcinoma) as template and PCR primers in exons 8 and 14 of p73. 4 Unexpectedly, our analysis showed that not all p73 splice variants present in the cDNA sample are detected in every PCR reaction. In the PCR reactions with the two lowest amounts of SCC15 cDNA, splice variants p73a, p73g and p73e were detected (Figure 1a ). In the PCR mixture containing the second highest amount of cDNA, a p73d band and a lower (221 bp) band appeared whereas p73a was hardly visible (Figure 1a) , while in the PCR reaction with the highest amount of cDNA the 221 bp band was the only band detected (Figure 1a) . The identity of splice variants was determined by sequencing (Figure 1b, data not shown) . Since the smallest C-terminal splice variant described in almost all p73 research and review articles is p73d 1, 5, 6 we focused specifically on the 221 bp band. Sequence analysis showed that the 221 bp band was indeed amplified from a genuine p73 splice variant, where exons 10, 11, 12 and 13 were spliced out (Figure 1b) . The same splice variant was described previously as p73Z in this journal by Scaruffi et al. 3 A schematic representation of the p73 splice variants including the p73Z form is presented in Figure 1c .
Scaruffi et al 3 have suggested a specific role for p73Z in the differentiation of acute lymphoblastic leukaemia (ALL) based on their finding that the expression of this variant is restricted to a small percentage of more differentiated B-cell ALL (This p73Z splice variant should not be confused for another splice variant first described by Ishimoto et al 5 , also denominated p73Z; this form is characterised by alternative termination, has a long exon 13 containing a stop codon and encodes a 571-amino-acid protein). Besides, its presence in SCC15 cells, the p73Z form was also detected in HaCaT (immortal keratinocyte cell line) and HCT116 (colorectal cancer cell line) cells (Figure 1d ). It was not detected in HeLa cells (cervix carcinoma cell line) and in cultured primary human cells (keratinocytes and fibroblasts), despite the use of high concentrations of cDNA in the PCR reaction. Hence, we found expression of p73Z in three out of four transformed cell lines analysed (Figure 1a and d) , but detection of p73Z (and other splice variants) depended strongly on the concentration of template used. This indicates that extreme care must be taken when making statements on the absence or presence of p73 splice variants from results obtained by RT-PCR. Our results demonstrate that when shorter splice variants of p73 are present in amplifiable amounts in the PCR mixture, larger splice variants become underrepresented during amplification (Figure 1a ). This PCR bias (Shagin, DA et al. Nucleic Acids Res 1999; 27, e23) cannot be circumvented by using more sophisticated PCR techniques such as real-time RT-PCR, which has the same preference towards the amplification of small splice variants as conventional RT-PCR.
In conclusion, we believe that RT-PCR of different splice variants of p73 can be used in a meaningful way for qualitative purposes, provided that care is taken to analyse various dilutions of the template cDNA. For quantitative purposes it will be imperative to design splice-variant specific primers to produce unique PCR fragments that can be quantified by real-time PCR. Only if these precautions are being taken, meaningful statements on possible links between specific p73 splice variants and a specific carcinogenic phenotype can be made.
